undamentalytics Newsletter

Satter Muneer A: insider trades

Officer, Director at 5 companies we cover. 44 open-market purchases and 1 sale not made under a pre-set plan, reported from June 4, 2014 to May 29, 2026.

Would copying Satter Muneer A’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 19 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on June 5, 2014 into $290 by November 2, 2026, −24.9% a year. The copy held shares only 45% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,562, +5.6% a year (the S&P 500 held throughout made $47,926, +13.5% a year). Beta against the index was 0.29. Twelve months after each report, the average purchase was −39.9% against the S&P 500 (median −36.6%), and 11% beat it. Measured from the trade date, the insider’s own timing, the average was −40.3%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 2014201620182020202220242026 $47.9k$19.6k$290
Copying Satter Muneer AS&P 500, same days investedS&P 500, held throughout $10,000 copying Satter Muneer A’s open-market purchases from June 5, 2014, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−24.9%
S&P 500, same days invested
+5.6% (held throughout +13.5%)
Time in shares
45%
Sharpe ratio (S&P 500)
−0.12 (0.70)
Biggest drop (S&P 500)
−99% (−34%)
Market sensitivity (beta)
0.29
Purchases copied
20

Trade by trade

Satter Muneer A: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 20 −9.0% −20.9% 35% 6 −0.31 0.77 No reliable evidence
Purchases, 6 months after the report 19 −21.6% −37.8% 21% 5 −1.73 0.16 No reliable evidence
Purchases, 12 months after the report 19 −39.9% −36.6% 11% 5 −3.45 0.026 Some evidence: behind
Purchases, 12 months after the trade 19 −40.3% −39.3% 11% 5 −3.76 0.020 Some evidence: behind
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Whitehawk Therapeutics, Inc. WHWK —130March 17, 2017January 10, 2019
Immunic, Inc. IMUX —111June 4, 2014September 17, 2018
Akebia Therapeutics, Inc. AKBA —120November 13, 2014July 11, 2017
Annexon, Inc. ANNX —60July 11, 2022May 29, 2026
Rein Therapeutics, Inc. RNTX See Remarks20June 9, 2020January 8, 2021

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 29, 2026May 28, 2026 ANNX Purchase $3,319,019 −12.9%not yetnot yet
November 21, 2025November 20, 2025 ANNX Purchase $3,600,784 not yetnot yetnot yet
November 19, 2025November 17, 2025 ANNX Purchase $5,055,000 not yetnot yetnot yet
December 28, 2023December 26, 2023 ANNX Purchase $1,008,000 not yetnot yetnot yet
February 14, 2023February 10, 2023 ANNX Purchase $17,999,994 +7.3%−35.5%−47.8%
July 11, 2022July 7, 2022 ANNX Purchase $9,423,314 not yetnot yetnot yet
January 8, 2021January 8, 2021 RNTX Purchase $9,900,000 not yetnot yetnot yet
June 9, 2020June 8, 2020 RNTX Purchase $4,070,000 not yetnot yetnot yet
January 10, 2019January 8, 2019 WHWK Purchase $150,154 not yetnot yetnot yet
January 7, 2019January 3, 2019 WHWK Purchase $127,600 not yetnot yetnot yet
January 2, 2019December 28, 2018 WHWK Purchase $108,200 not yetnot yetnot yet
December 27, 2018December 21, 2018 WHWK Purchase $104,000 not yetnot yetnot yet
December 20, 2018December 18, 2018 WHWK Purchase $115,200 not yetnot yetnot yet
December 14, 2018December 12, 2018 WHWK Purchase $121,400 not yetnot yetnot yet
December 11, 2018December 7, 2018 WHWK Purchase $127,200 not yetnot yetnot yet
December 6, 2018December 3, 2018 WHWK Purchase $125,400 not yetnot yetnot yet
November 30, 2018November 28, 2018 WHWK Purchase $118,600 not yetnot yetnot yet
September 17, 2018September 13, 2018 IMUX Sale $4,149,085 not yetnot yetnot yet
June 29, 2018June 28, 2018 WHWK Purchase $7,000,001 not yetnot yetnot yet
March 23, 2018March 21, 2018 WHWK Purchase $24,400 not yetnot yetnot yet
March 21, 2018March 19, 2018 WHWK Purchase $64,534 −23.1%−85.5%−85.1%
December 14, 2017December 12, 2017 IMUX Purchase $548,500 +5.1%−93.3%−96.8%
December 11, 2017December 7, 2017 IMUX Purchase $732,500 −7.1%−96.8%−96.4%
September 14, 2017September 12, 2017 IMUX Purchase $521,000 not yetnot yetnot yet
September 12, 2017September 8, 2017 IMUX Purchase $176,500 not yetnot yetnot yet
July 11, 2017July 5, 2017 AKBA Purchase $14,999,989 +29.6%−45.3%−46.0%
June 14, 2017June 13, 2017 IMUX Purchase $61,300 not yetnot yetnot yet
June 12, 2017June 8, 2017 IMUX Purchase $93,300 not yetnot yetnot yet
June 7, 2017June 6, 2017 IMUX Purchase $64,000 not yetnot yetnot yet
March 27, 2017March 27, 2017 IMUX Purchase $15,000,000 not yetnot yetnot yet
March 17, 2017March 15, 2017 WHWK Purchase $5,600,000 not yetnot yetnot yet
October 29, 2015October 28, 2015 IMUX Purchase $2,200,000 +22.2%−35.6%−41.9%
April 22, 2015April 22, 2015 AKBA Purchase $3,465,000 +26.5%+9.7%+12.7%
November 26, 2014November 25, 2014 AKBA Purchase $65,900 −24.0%−13.9%−25.5%
November 25, 2014November 24, 2014 AKBA Purchase $69,400 −33.5%−19.9%−29.9%
November 24, 2014November 21, 2014 AKBA Purchase $73,650 −31.7%−25.5%−37.4%
November 21, 2014November 20, 2014 AKBA Purchase $73,500 −33.7%−29.9%−39.7%
November 20, 2014November 19, 2014 AKBA Purchase $74,250 −36.2%−37.4%−45.4%
November 19, 2014November 18, 2014 AKBA Purchase $69,200 −36.8%−39.7%−39.3%
November 18, 2014November 17, 2014 AKBA Purchase $64,700 −38.5%−45.4%−36.6%
November 17, 2014November 14, 2014 AKBA Purchase $59,550 −31.3%−39.3%−32.3%
November 14, 2014November 13, 2014 AKBA Purchase $57,800 −25.7%−36.6%−27.7%
November 13, 2014November 12, 2014 AKBA Purchase $59,515 −18.7%−32.3%−32.5%
October 9, 2014October 8, 2014 IMUX Purchase $1,300,005 +54.5%−74.1%−75.5%
June 4, 2014June 2, 2014 IMUX Purchase $190,811 +28.2%+18.8%+57.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Satter Muneer A traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.